Whether the addition of intravenous thrombolysis (IVT) adds benefit beyond what can be achieved with mechanical thrombectomy (MT) alone is still a topic of worldwide debate. While the use of IVT prior to thrombectomy is the current recommended standard of care approach, many experts have questioned if its use truly results in better outcomes. Numerous large scale clinical trials have been conducted, with the majority reporting inconclusive findings.

The non-inferiority design of many trials in this space has led to many debates on the best way forward, given the challenges that come with interpreting non-inferiority study findings. Professionals have pointed out that if thrombectomy came first, there would be insufficient evidence to prove that thrombolysis should be added on, but removing an established treatment from the standard of care approach is much more difficult.

In this episode, key opinion leaders debate the value of bridging therapy for MT following recent reports from several large scale studies. What evidence do we have and what is the best way forward? 

With Manon Kappelhof, Johannes Kaesmacher, Urs Fischer, Yvo B. Roos, and Thanh Nguyen.